Abstract:Baicalin is a flavone glycoside that possess numerous pharmacological properties including anti-inflammatory, anti-cancer and anti-pruritic effects. Based on these properties, we investigated whether baicalin could be used to alleviate kidney fibrosis induced by diabetes mellitus. Using a streptozotocin (STZ)-induced diabetic mouse model, we found that baicalin treatment could suppress diabetes-enhanced water consumption, urine volume production, blood urea nitrogen (BUN), serum creatinine and urinary albumin/urinary creatinine (UACR). Correspondingly, baicalin treatment could significantly maintain the morphology of the glomerulus and renal tubules in diabetes-induced kidney lesions by repressing WT1 and Nephrin expressions in the glomeruli, as well as LTL, caspases-9 and Fas expressions in the renal tubules. We also determined that baicalin could suppress inflammation responses and reduced MDA activities that were enhnaced by diabetes while increasing SOD, CAT, GPX and Nrf2 expressions that were inversely lowered. We demonstrated the presence of interstitial fibrosis in the diabetic kidney but this could be alleviated by baicalin which downregulated ɑ-SMA and TGF-β1 expressiond (key pro-fibrotic markers). We investigated Klotho a transmembrane protein that is expressed by renal tubule epithelial cells. Secreted form of Klotho could bind to TGF-β1 receptors and block the TGFβ1 signaling pathway. We determined that hypermethylation of the Klotho promoter plays an important role in baicalin's ability to rescue renal fibrosis induced by diabetes mellitus. In sum, our results showed that baicalin could alleviate renal fibrosis-induced by diabetes through partly modulating Klotho promoter methylation. Funding Statement: This study was supported by NSFC grant (31771331, 81741016), Science and Technology Planning Project of Guangdong Province (2017A050506029, 2017A020214015, 2016B030229002), Science and Technology Program of Guangzhou (201710010054), Guangdong Natural Science Foundation (2016A030311044), Project of National University Students Challenge Cup (18112003). Declaration of Interests: The authors declare that there are no competing financial interests. Ethics Approval Statement: This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Ethic Committee at Jinan University.

Therapeutic mechanism of baicalein in peritoneal dialysis-associated peritoneal fibrosis based on network pharmacology and experimental validation

Crocin Ameliorates Peritoneal Fibrosis in Rat Induced by Peritoneal Dialysis Via Wnt5a/β-Catenin Pathway

Baicalein Ameliorates Renal Interstitial Fibrosis by Inducing Myofibroblast Apoptosis in Vivo and in Vitro.

Baicalin - 2- ethoxyethyl ester alleviates renal fibrosis by inhibiting PI3K/AKT/NF-κB signaling pathway

Baicalin and baicalein attenuate renal fibrosis in vitro via inhibition of the TGF-β1 signaling pathway

Baicalein Attenuates Renal Fibrosis by Inhibiting Inflammation Via Down-Regulating NF-κB and MAPK Signal Pathways.

Protective Effects of Baicalin on Diabetes Mellitus-Induced Renal Fibrosis in Mice

Baicalin ameliorates renal fibrosis by upregulating CPT1α-mediated fatty acid oxidation in diabetic kidney disease

Therapeutic Targeting of GSK3β-Regulated Nrf2 and NFκB Signaling Pathways by Salvianolic Acid A Ameliorates Peritoneal Fibrosis

Baicalein improves renal interstitial fibrosis by inhibiting the ferroptosis in vivo and in vitro

Exploration of the potential mechanism of Baicalin for hepatic fibrosis based on network pharmacology, gut microbiota, and experimental validation

Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin

The Effect of Baicalein on the Nf-Kappa B/P65 Expression in the Peripheral Blood of Patients with Diabetic Nephropathy and in Vitro

Antifibrotic Effects of Chronic Baicalein Administration in a CCl4 Liver Fibrosis Model in Rats

The Therapeutic Effects of Baicalein on the Hepatopulmonary Syndrome in the Rat Model of Chronic Common Bile Duct Ligation

Baicalin reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal injury in type 1 diabetic mouse model

Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis

Baicalein Attenuates Bleomycin-Induced Pulmonary Fibrosis in Rats Through Inhibition of Mir-21.

Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling

Betulinic acid ameliorates experimental diabetic-induced renal inflammation and fibrosis via inhibiting the activation of NF-κB signaling pathway

Baicalin alleviates bleomycin-induced early pulmonary fibrosis in mice via the mitoKATP signaling pathway